Q1 FY2027 EarningsFQ1 2027 results showed significant misses across key profitability metrics despite revenue lining up with the $0 consensus. Net loss widened to $3.2M (vs. ~$2.8M expected) and GAAP EPS of -$0.83 matched the lone analyst estimate, but operating loss of $2.9M significantly exceeded the $2.6M consensus due to transaction costs and inventory write-downs. The transition toward the Fortitude business combination in Q4 2026 and the shift to the MyoVista Insights software platform are currently overshadowing legacy hardware operations, which saw a $0.3M impairment.
Financial report interval: 2026.05.01 - 2026.07.31
Overview: HeartSciences(HSCS) the Revenue is 2.1 K (+10.53%), Beat estimate;the EBIT is -2.939 M (-56.83%), Miss estimate;the EPS is -0.86 (+45.57%), Miss estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueExceed expectations
0.00B10.53%
0.00B100.00%
+0.00B110.53%
EBITMiss expectations
-0.00B56.83%
-0.00B38.73%
-0.00B18.10%
EPSMiss expectations
-0.8645.57%
-0.8347.47%
-0.03001.90%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf